SCHEMBL8180878

SCHEMBL8180878

CC(C)c1cccc(-c2cccc(C(=O)c3oc4ccccc4c3CC(=O)O)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.43
▸ RXRB P28702 1/20 0.43
▸ RXRG P48443 1/20 0.43
▸ MAPT P10636 8/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPSR1 Q6W5P4 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ PTPN1 P18031 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CYP2C19 P33261 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8167631 0.83 RXRA (0.48) RXRARXRBMAPTNPC1KMT2A
SCHEMBL8179582 0.82 MAPT (0.44) RXRARXRBRXRGMAPTNPC1
SCHEMBL8174960 0.79 MTNR1A (0.46) RXRARXRBRXRGMAPTPTPN1
SCHEMBL8167630 0.78 MAPT (0.43) RXRARXRBRXRGMAPTNPC1
SCHEMBL8167484 0.78 PTPN1 (0.56) MAPTNPC1KMT2AALDH1A1TSHR
SCHEMBL8175782 0.77 ALDH1A1 (0.47) MAPTNPC1KMT2AALDH1A1NPSR1
SCHEMBL8171692 0.77 KDM4E (0.46) RXRARXRBRXRGMAPTKMT2A
SCHEMBL4254952 0.71 MAPT (0.40) MAPTNPC1KMT2AALDH1A1NPSR1
SCHEMBL4602193 0.69 RXRA (0.78) RXRARXRBRXRGGAA
SCHEMBL4193857 0.68 KDM4E (0.68) MAPTNPC1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS RXRA 3555/4885RXRB 3327/4885RXRG 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback